Altre lingue 23andMe Holding Co.

Azioni

ME

US90138Q1085

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 10/07/2024			Variaz. 5gg	Var. 1 gen.
0,46 ^USD	+2,75%		+8,24%	-49,64%

28/06	23andMe offrirà analisi del sangue gratuite ai membri in un programma pilota	MT
28/06	23andMe Holding Co. e Nightingale Health Plc annunciano una collaborazione strategica per pilotare il pannello di biomarcatori del sangue	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

23andMe to Offer Free Blood Testing for Members in Pilot Program	28/06
Inside Information: 23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel	28/06
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel	28/06
23andMe Holding Co. and Nightingale Health Plc Announce Strategic Collaboration to Pilot Blood Biomarker Panel	28/06
Sector Update: Health Care Stocks Advance Late Afternoon	10/06
Sector Update: Health Care Stocks Retreat Monday Afternoon	10/06
23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October Data Breach	10/06
23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October 2023 Data Breach	10/06
Canada, UK launched joint probe into 23andMe data breach, says Canada	10/06
23andMe Faces Joint Probe From UK Information Commissioner's Office, Canada's Privacy Commissioner Office Over 2023 Data Breach	10/06
23andMe Launches New Genetic Report on Bipolar Disorder	05/06
23andMe Launches New Genetic Report on Bipolar Disorder	05/06
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community	04/06
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting	03/06
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting	03/06
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, Targeting CD200R1, at the 2024 ASCO Annual Meeting	03/06
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history	29/05
Earnings Flash (ME) 23ANDME Reports Q4 Revenue $64M, vs. Street Est of $61.5M	23/05
23andMe Q4 Loss Widens, Revenue Decreases	23/05
23andMe Holding Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	23/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

Anne Wojcicki su antenati, salute e genoma umano

13 luglio 2023 alle 20:26